Current and Future Cell Therapy Standards and Guidelines
- PMID: 31466608
- DOI: 10.1016/j.hoc.2019.05.008
Current and Future Cell Therapy Standards and Guidelines
Abstract
Cell biology researchers, cellular engineers, and clinicians are teaming together to create powerful drugs. The use of cell-derived products as biologics is rapidly advancing. These human cell-based products have great potential for treating serious conditions but may have unidentified risks. Manipulations, expansions, and gene modifications increase the risks of unexpected outcomes. Implementation of the 21st Century Cures Act is opening avenues for accelerated approvals of these drugs for use in clinical trials and licensure. Although overwhelming, collaboration between regulators, industry, and research and medical communities enables the field to safely meet the needs of critically ill patients.
Keywords: Biologic drug products; Cellular therapies; HCT/Ps; Licensure requirements; PHS 351 and 361.
Published by Elsevier Inc.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources